Frontiers in Immunology (Nov 2024)

Telitacicept in combination with B-cell depletion therapy in MuSK antibody-positive myasthenia gravis: a case report and literature review

  • Jia Wang,
  • Haotao Zheng,
  • Jia Wei,
  • Jiaping Wu,
  • Ziyang Feng,
  • Xueqin Chen,
  • Yangsicheng Liu,
  • Wenxin Qin,
  • Xiude Qin,
  • Fanxin Kong

DOI
https://doi.org/10.3389/fimmu.2024.1456822
Journal volume & issue
Vol. 15

Abstract

Read online

Muscle-specific kinase (MuSK) myasthenia gravis (MG) is relatively rare and has a higher incidence of myasthenic crisis compared with other subtypes. However, there is still a lack of effective treatment for refractory MuSK MG. We report the case of a 70-year-old female MuSK MG patient with recurrent fluctuations who stabilized on telitacicept in combination with anti-CD20 B-cell depletion therapy. This combination regimen deserves further investigation. Furthermore, we summarized the treatment protocols of 14 previously reported cases of MuSK MG.

Keywords